Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

INK Edge Outlook

Mostly sunny as of July 01, 2019
For the latest outlook, get the company report
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for IPA within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 15, 2019 08:30 ET
ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals
VICTORIA, July 15, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF), an industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that it has entered into a new antibody discovery collaboration with Entos Pharmaceuticals Inc., to develop a therapeutic candidate against an undisclosed, immuno-oncology target, by leveraging ImmunoPrecise's proprietary B cell Select™ platform.
Read full article
Jun 26, 2019 08:15 ET
ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform
VICTORIA, June 26, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that from this point forward it will guarantee the success of campaigns powered by its proprietary B cell Select™ Antibody Discovery platform. 
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.71
--
--
Price to Sales - TTM
4.38
13.18
15.54
Price to Book - most recent quarter
2.20
3.60
3.07
Price to Cash Flow per share - TTM
--
--
15.64
Price to Free Cash Flow per share - TTM
--
--
16.52
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 2019761-7,399
Jun 15, 20198,160-5,726
May 31, 201913,886-71,633
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Immunoprecise Antibodies Ltd, formerly Tanqueray Exploration Ltd, is a Canada-based supplier of custom hybridoma development services. The Company's geographical segments include United States of America and Canada. It offers products, such as antibodies and hybridoma licensing. It offers various services, such as ImmunoProtect, Monoclonal Development, Polyclonal Development, Antibody Protection, Peptide Production and Cryopreservation Services. Its antibody products include IPA006A, IPA006B and IPA006F, which it offers to the research and industrial community. Its hybridoma licensing products include Anti-Human P38a (MAPKinase) Monoclonal Antibody Hybridoma Cell Line and Anti-Acetylated Lysine Monoclonal Antibody Hybridoma Cell Line. It offers cryopreservation storage service for the secure storage of users' valuable biological materials, including hybridoma clones, plasmid constructs and cell lines. It also offers both peptide synthesis and protein carrier conjugation services.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $IPA.CA IPA.V

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $IPA.CA IPA.V

  • No tweets found